乳腺癌与缺血性卒中风险的时间依赖性关联:全国性队列研究
该研究利用韩国国民健康保险服务数据库开展全国性回顾性匹配队列研究,纳入107,606例乳腺癌手术后幸存者与322,818例无癌匹配女性。平均随访7.2年发现,乳腺癌诊断后短期内缺血性卒中风险升高,1年sHR为1.59,随后逐渐下降,长期风险略低于无癌女性。
要点
- 乳腺癌诊断后1年内卒中风险升高(sHR 1.59),3个月和6个月时关联最强。
- 长期幸存者卒中风险略低(1年landmark分析sHR 0.87)。
- 蒽环类药物和他莫昔芬联合芳香化酶抑制剂治疗与卒中风险升高相关。
核心结论
- 乳腺癌与缺血性卒中风险的关联具有时间依赖性,诊断和治疗后短期升高,随后逐渐下降。
研究设计与样本
- 韩国全国性回顾性匹配队列研究,乳腺癌手术幸存者107,606例按出生年份1:3匹配无癌女性322,818例,平均随访7.2年。
主要发现
- 乳腺癌幸存者1年内缺血性卒中风险升高(sHR 1.59;95%CI 1.34-1.89),3年时sHR为1.17(95%CI 1.05-1.30)。
- 3个月和6个月时所有年龄组关联更强;长期幸存者风险略低(sHR 0.94;95%CI 0.88-1.00)。
- 1年landmark分析中风险更低(sHR 0.87;95%CI 0.81-0.93)。
- 幸存者中蒽环类药物(sHR 1.25)和他莫昔芬联合芳香化酶抑制剂(sHR 1.49)与卒中风险升高相关,放疗与风险降低相关(sHR 0.84),1年后关联减弱且不再显著。
- 低收入的幸存者以及合并高血压、糖尿病或当前吸烟的幸存者卒中风险更高。
关键数值与推荐
- 缺血性卒中定义为住院且具有ICD-10编码I63/I64并接受住院脑CT或MRI检查。
- 采用Fine-Gray模型估计亚分布风险比(sHR)及95%CI,以死亡为竞争风险,并调整社会人口学因素及心血管和非心血管合并症。
临床怎么用
- 对乳腺癌幸存者应在诊断后早期进行心血管评估并持续监测血栓栓塞事件。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The association between breast cancer diagnosis and treatment and the risk of incident ischemic stroke remains unclear. We investigated ischemic stroke risk among breast cancer survivors and evaluated associations by age, follow-up duration, and type of cancer treatment. METHODS: We conducted a nationwide, retrospective, matched cohort study using the Korean National Health Insurance Service database. Women aged 18 years and older with newly diagnosed breast cancer who underwent breast cancer surgery between January 2010 and December 2016 and had no prior stroke were identified. Each was matched 1:3 by birth year to cancer-free women. The primary outcome was first ischemic stroke, defined as hospitalization with International Classification of Disease, Tenth Revision codes I63/I64 plus inpatient brain CT or MRI. Subdistribution hazard ratios (sHRs) and 95% CIs were estimated using Fine-Gray models that accounted for death as a competing risk and adjusted for sociodemographic factors and cardiovascular and non-CV comorbidities. RESULTS: We analyzed 107,606 breast cancer surgery survivors (mean age, 50.0 years) and 322,818 matched cancer-free women. Over a mean 7.2-year follow-up, ischemic stroke occurred in 1,155 survivors (1.07%). Stroke risk was elevated shortly after breast cancer diagnosis (1-year sHR 1.59; 95% CI 1.34-1.89; 3-year sHR 1.17; 95% CI 1.05-1.30) compared with cancer-free women, with stronger associations at 3 and 6 months after diagnosis across all age groups. Over the long term, survivors had a slightly lower risk of stroke (sHR 0.94; 95% CI 0.88-1.00), and in a 1-year landmark analysis including only event-free individuals, the risk was lower (sHR 0.87, 95% CI 0.81-0.93). Among survivors, anthracycline use (sHR 1.25) and combined tamoxifen-aromatase inhibitor therapy (sHR 1.49) were associated with increased risk of stroke, whereas radiation therapy was associated with decreased risk (sHR 0.84). These associations attenuated and became nonsignificant beyond 1 year. Stroke risk was also higher among survivors with low income, hypertension, diabetes, or current smoking. DISCUSSION: The association between breast cancer and ischemic stroke risk is time dependent, with a short-term increase after diagnosis and treatment followed by a gradual decline over time. These findings highlight the need for proactive stroke risk management, including early CV assessment and ongoing monitoring for thromboembolic events during survivorship.
引用
- Park YM, Jung W, Kim BS, et al. Time-Dependent Association Between Breast Cancer and Risk of Ischemic Stroke: A Nationwide Cohort Study. Neurology. 2026. PMID: 42308440. doi:10.1212/WNL.0000000000218165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。